Yahoo Finance HTG Molecular Diagnostics Reports First Quarter 2020 Results
Call scheduled for today, May 13, at 4:30pm ET
TUCSON, Ariz., May 13, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2020.
“With the COVID-19 pandemic impacting businesses globally, the first quarter of 2020 was unlike anything we would have anticipated. As work from home restrictions directly impacted our customers and their normal ordering patterns, we felt the immediate impact,” said John Lubniewski, President and CEO of HTG. “However, we have managed to take advantage of this time to leverage our teams, improve our processes, and accomplish detailed long-term planning all in preparation of emerging from this period as a stronger company. While we cannot be certain of the ultimate impact of the COVID-19 pandemic on us or our customers, we are optimistic that demand for our products and services will return.”
Mr. Lubniewski continued, “Our product development teams have made progress towards the key milestones that we had set for ourselves during the quarter. Our California and Arizona development teams continue to implement our development strategy and we are on track to deliver development milestones. While the pandemic has created some near-term uncertainty, we are very proud of how our employees have faced the challenges – with flexibility and a commitment to ensuring our long-term success. When our customers eventually return to a more normal work environment, we will be prepared to meet demand and for growth in our business.”
First Quarter 2020 Financial Highlights:
Total revenue for the first quarter ended March 31, 2020 was $2.2 million, compared with $3.2 million for the same period in 2019. The decrease in revenue is a result of the impact of the COVID-19 pandemic requiring the closure of customer facilities around the globe. These closures limited the company’s ability to deliver its products to customer facilities and created challenges for customers in preparing and shipping samples to the company for processing.
Product and product-related services revenue was $2.0 million, compared with $2.7 million for the same period in 2019. This decrease in direct revenue primarily reflects a decline in lower margin, subcontracted laboratory services revenue reflected in RUO sample processing revenue when compared with first quarter of 2019 revenue.
Collaborative development services revenue for the quarter ended March 31, 2020 was $0.2 million compared with $0.5 million for the same period in 2019. The decrease in collaborative development services revenue reflects a decrease in activity as partners approached key decision points in current active programs.
Net loss from operations for the first quarter ended March 31, 2020 was $5.4 million, compared with $5.3 million for the first quarter of 2019. Net loss per share was $(0.08) for the first quarter of 2020 compared with $(0.19) for the first quarter of 2019.
Cash, cash equivalents and short-term available-for-sale securities totaled $32.0 million as of March 31, 2020, with current liabilities of approximately $8.4 million and non-current liabilities of $11.6 million. An additional $3.3 million of restricted cash was held in connection with a convertible note that is included in current liabilities as of March 31, 2020.
Conference Call and Webcast:
HTG will host a conference call for the investment community today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details are as follows:
Date: | Wednesday, May 13, 2020 | |
Time: | 4:30 p.m. Eastern Time | |
Toll Free: | (877) 407-0789 | |
International: | (201) 689-8562 | |
Conference ID: | 13703169 | |
Webcast: |
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our being on track to deliver development milestones and our expectations for increased demand for our products and services in the future and our ability to meet those demands. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the impact of the COVID-19 pandemic on the company and its customers; the risk that products that we expect to develop in 2020 are not developed or released; the risk that we may not establish new and significant collaboration development arrangements; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the year ended December 31, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contact:
Ashley Robinson
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
-Financial tables follow-
HTG Molecular Diagnostics, Inc. | |||||||
Condensed Consolidated Statements of Operations | |||||||
(Unaudited) | |||||||
Three Months Ended March 31, | |||||||
2020 | 2019 | ||||||
Revenue: | |||||||
Product and product-related services | $ | 1,988,137 | $ | 2,662,505 | |||
Collaborative development services | 237,337 | 540,320 | |||||
Total revenue | 2,225,474 | 3,202,825 | |||||
Operating expenses: | |||||||
Cost of product and product-related services revenue | 1,015,492 | 2,045,527 | |||||
Selling, general and administrative | 4,675,263 | 4,400,866 | |||||
Research and development | 1,926,275 | 2,074,748 | |||||
Total operating expenses | 7,617,030 | 8,521,141 | |||||
Operating loss | (5,391,556 | ) | (5,318,316 | ) | |||
Other income (expense), net | (61,166 | ) | (52,530 | ) | |||
Net loss before income taxes | (5,452,722 | ) | (5,370,846 | ) | |||
Provision for income taxes | (5,176 | ) | — | ||||
Net loss | $ | (5,457,898 | ) | $ | (5,370,846 | ) | |
Net loss per share, basic and diluted | $ | (0.08 | ) | $ | (0.19 | ) | |
Shares used in computing net loss per share, basic and diluted | 64,567,932 | 28,600,679 | |||||
HTG Molecular Diagnostics, Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
March 31, | December 31, | |||||||
2020 | 2019 | |||||||
Assets | (Unaudited) | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 10,403,697 | $ | 7,619,748 | ||||
Short-term investments available-for-sale, at fair value | 21,554,318 | 25,410,222 | ||||||
Restricted cash | 3,270,247 | 3,270,247 | ||||||
Accounts receivable | 1,202,469 | 3,164,176 | ||||||
Inventory, net | 1,637,898 | 1,269,667 | ||||||
Prepaid expenses and other | 525,647 | 633,522 | ||||||
Total current assets | 38,594,276 | 41,367,582 | ||||||
Operating lease right-of-use assets | 1,039,045 | 1,209,145 | ||||||
Property and equipment, net | 2,169,663 | 2,240,133 | ||||||
Other non-current assets | 123,086 | 302,409 | ||||||
Total assets | $ | 41,926,070 | $ | 45,119,269 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,666,819 | $ | 1,662,583 | ||||
Accrued liabilities | 1,195,827 | 1,870,296 | ||||||
Contract liabilities - current | 409,449 | 426,014 | ||||||
NuvoGen obligation - current | 1,093,592 | 1,152,233 | ||||||
MidCap Term Loan payable - current | 280,000 | — | ||||||
Convertible note - current, net of debt issuance costs | 2,991,031 | 2,987,667 | ||||||
Operating lease liabilities - current | 696,301 | 758,932 | ||||||
Other current liabilities | 36,205 | 41,134 | ||||||
Total current liabilities | 8,369,224 | 8,898,859 | ||||||
NuvoGen obligation - non-current, net of discount | 4,265,991 | 4,498,777 | ||||||
MidCap Term Loan payable - net of discount and debt issuance costs | 6,629,972 | 6,871,545 | ||||||
Operating lease liabilities - non-current | 512,718 | 636,340 | ||||||
Other non-current liabilities | 234,981 | 244,114 | ||||||
Total liabilities | 20,012,886 | 21,149,635 | ||||||
Commitments and Contingencies | ||||||||
Total stockholders’ equity | 21,913,184 | 23,969,634 | ||||||
Total liabilities and stockholders' equity | $ | 41,926,070 | $ | 45,119,269 | ||||
